Lisa Anne Bero, PhD

Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF

bero@medicine.ucsf.edu

Phone: (415) 476-1067 (voice)
Box 0613, UCSF

View on UCSF Profiles

Education

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)

Professional Experience

• 1988-1992
  Pew Fellowship, Institute for Health Policy Studies, UCSF
• 1994-present
  Co-Director, San Francisco Cochrane Center
• 6/00-present
  Vice Chair, Department of Clinical Pharmacy, UCSF
• 6/01-present
  Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

• 1994-1992
  Special Consultant to the European Union Committee on Technology Assessment
• 1992
  Best article published in 1996 in the Intl J Technology Assessment in Health Care
• 1992
  Special consultant to the World Bank for a background paper on Tobacco Control Policies
• 2000-2001, 2002
  Special Advisor to World Health Organization

Selected Publications

1. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ. 2013; 346:f2231.
   View on PubMed
2. Bero L. Industry sponsorship and research outcome: a cochrane review. JAMA Intern Med. 2013 Apr 8; 173(7):580-1.
   View on PubMed
3. Nguyen NY, Bero L. Medicaid drug selection committees and inadequate management of conflicts of interest. JAMA Intern Med. 2013 Mar 11; 173(5):338-43.
   View on PubMed
4. Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilisation and costs in low- and middle-income countries. Cochrane Database Syst Rev. 2013; 2:CD010398.
   View on PubMed
5. Odierna DH, Forsyth SR, White J, Bero LA. The cycle of bias in health research: a framework and toolbox for critical appraisal training. Account Res. 2013; 20(2):127-41.
   View on PubMed
6. Taba P, Rosenthal M, Habicht J, Tarien H, Mathiesen M, Hill S, Bero L. Barriers and facilitators to the implementation of clinical practice guidelines: A cross-sectional survey among physicians in Estonia. BMC Health Serv Res. 2012; 12:455.
   View on PubMed
7. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012; 12:MR000033.
   View on PubMed
8. Bero L, Busuttil G, Farquhar C, Koehlmoos TP, Moher D, Nylenna M, Smith R, Tovey D. Measuring the performance of the cochrane library. Cochrane Database Syst Rev. 2012; 12:ED000048.
   View on PubMed
9. Bero LA, Hill S, Habicht J, Mathiesen M, Starkopf J. The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines. J Clin Epidemiol. 2013 Feb; 66(2):132-9.
   View on PubMed
10. Bero LA, Binder L. The Cochrane Collaboration review prioritization projects show that a variety of approaches successfully identify high-priority topics. J Clin Epidemiol. 2013 May; 66(5):472-3.
    View on PubMed
11. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012; 345:e5155.
    View on PubMed
12. Anson A, Ramay B, de Esparza AR, Bero L. Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala. Global Health. 2012; 8:22.
    View on PubMed
13. Hill S, Yang A, Bero L. Priority medicines for maternal and child health: a global survey of national essential medicines lists. PLoS One. 2012; 7(5):e38055.
    View on PubMed
14. Norris SL, Burda BU, Holmer HK, Ogden LA, Fu R, Bero L, Schünemann H, Deyo R. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol. 2012 Jul; 65(7):725-33.
    View on PubMed
15. Malone RE, Grundy Q, Bero LA. Tobacco industry denormalisation as a tobacco control intervention: a review. Tob Control. 2012 Mar; 21(2):162-70.
    View on PubMed
16. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012; 344:d7202.
    View on PubMed
17. Sutton P, Woodruff TJ, Vogel S, Bero LA. Conrad and Becker's "10 Criteria" fall short of addressing conflicts of interest in chemical safety studies. Environ Health Perspect. 2011 Dec; 119(12):A506-7; author reply A508-9.
    View on PubMed
18. Walleser S, Hill SR, Bero LA. Characteristics and quality of reporting of cluster randomized trials in children: reporting needs improvement. J Clin Epidemiol. 2011 Dec; 64(12):1331-40.
    View on PubMed
19. Krleža-Jeriç K, Lemmens T, Reveiz L, Cuervo LG, Bero LA. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica. 2011 Jul; 30(1):87-96.
    View on PubMed
20. Millar TP, Wong S, Odierna DH, Bero LA. Applying the essential medicines concept to US preferred drug lists. Am J Public Health. 2011 Aug; 101(8):1444-8.
    View on PubMed

View on UCSF Profiles